Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00720941 · OUTCOME

Summary of Analysis for the Cancer Treatment Satisfaction Questionnaire (CTSQ) Score at Day 28 of Cycles 1-4

Pazopanib Versus Sunitinib in the Treatment of Locally Advanced and/or Metastatic Renal Cell Carcinoma · Source last updated 2025-03-30

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEAN
Unit
Scores on a scale
Interval / dispersion
Standard Deviation
Time frame
Day 28 of Cycles 1-4 (average of Weeks 4, 10, 16, and 22, respectively)

What was measured

The CTSQ assesses 3 domains related to the participant's satisfaction with cancer therapy: Expectations of Therapy (ET), Feelings about Side Effects (FSE), and Satisfaction with Therapy (SWT). Participants shared their thoughts on their cancer therapy (9 questions), their satisfaction with their most recently administered cancer therapy (6 questions), and if they would take the same cancer therapy if given the choice to do so again. All questions were assessed on a 5-point scale; 1, never; 5, always. Scores were averaged and transformed to a 0-100 scale; higher scores represent better treatment satisfaction.

Analysis population: Intent-to-Treat (ITT) Population. Analysis was based on the assigned randomized treatment, not on the actual treatment received/not received. Participants missing scores at early time points were excluded from the analysis at those time points. Mean total score was calculated at each assessment week.

Groups in this outcome

Pazopanib 800 mg

Participants were administered pazopanib 800 mg (2 x 400 mg tablets) orally OD continuously. Pazopanib was to be taken at least one hour before or at least two hours after a meal. Participants received study treatment until disease progression, death, unacceptable toxicity, or withdrawal of consent for any other reasons.

Sunitinib 50 mg

Participants were administered sunitinib 50 mg orally once daily in 6-week cycles (4 weeks of treatment, followed by 2 weeks without treatment). Participants received study treatment until disease progression, death, unacceptable toxicity, or withdrawal of consent for any other reasons.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Pazopanib 800 mg383
Sunitinib 50 mg386

Reported measurements

ET, Week 4 (n=383,386)

Analysis denominator · Participants

GroupSource count
Pazopanib 800 mg383
Sunitinib 50 mg386
Values in Scores on a scale · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Pazopanib 800 mg71.722.13Not reportedNot reportedNot reported
Sunitinib 50 mg71.322.38Not reportedNot reportedNot reported
ET, Week 10 (n=321,346)

Analysis denominator · Participants

GroupSource count
Pazopanib 800 mg321
Sunitinib 50 mg346
Values in Scores on a scale · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Pazopanib 800 mg73.421.62Not reportedNot reportedNot reported
Sunitinib 50 mg73.419.37Not reportedNot reportedNot reported
ET, Week 16 (n=296,293)

Analysis denominator · Participants

GroupSource count
Pazopanib 800 mg296
Sunitinib 50 mg293
Values in Scores on a scale · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Pazopanib 800 mg73.921.56Not reportedNot reportedNot reported
Sunitinib 50 mg72.921.43Not reportedNot reportedNot reported
ET, Week 22 (n=250,250)

Analysis denominator · Participants

GroupSource count
Pazopanib 800 mg250
Sunitinib 50 mg250
Values in Scores on a scale · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Pazopanib 800 mg73.021.40Not reportedNot reportedNot reported
Sunitinib 50 mg73.420.43Not reportedNot reportedNot reported
FSE, Week 4 (n=340,360)

Analysis denominator · Participants

GroupSource count
Pazopanib 800 mg340
Sunitinib 50 mg360
Values in Scores on a scale · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Pazopanib 800 mg66.324.00Not reportedNot reportedNot reported
Sunitinib 50 mg58.523.59Not reportedNot reportedNot reported
FSE, Week 10 (n=298,323)

Analysis denominator · Participants

GroupSource count
Pazopanib 800 mg298
Sunitinib 50 mg323
Values in Scores on a scale · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Pazopanib 800 mg66.023.09Not reportedNot reportedNot reported
Sunitinib 50 mg56.022.23Not reportedNot reportedNot reported
FSE, Week 16 (n=274,277)

Analysis denominator · Participants

GroupSource count
Pazopanib 800 mg274
Sunitinib 50 mg277
Values in Scores on a scale · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Pazopanib 800 mg65.023.01Not reportedNot reportedNot reported
Sunitinib 50 mg56.622.02Not reportedNot reportedNot reported
FSE, Week 22 (n=235, 232)

Analysis denominator · Participants

GroupSource count
Pazopanib 800 mg235
Sunitinib 50 mg232
Values in Scores on a scale · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Pazopanib 800 mg67.122.62Not reportedNot reportedNot reported
Sunitinib 50 mg57.821.28Not reportedNot reportedNot reported
SWT, Week 4 (n=355,374)

Analysis denominator · Participants

GroupSource count
Pazopanib 800 mg355
Sunitinib 50 mg374
Values in Scores on a scale · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Pazopanib 800 mg80.915.49Not reportedNot reportedNot reported
Sunitinib 50 mg79.015.23Not reportedNot reportedNot reported
SWT, Week 10 (n=309,336)

Analysis denominator · Participants

GroupSource count
Pazopanib 800 mg309
Sunitinib 50 mg336
Values in Scores on a scale · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Pazopanib 800 mg84.513.74Not reportedNot reportedNot reported
Sunitinib 50 mg80.415.15Not reportedNot reportedNot reported
SWT, Week 16 (n=287,284)

Analysis denominator · Participants

GroupSource count
Pazopanib 800 mg287
Sunitinib 50 mg284
Values in Scores on a scale · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Pazopanib 800 mg85.314.77Not reportedNot reportedNot reported
Sunitinib 50 mg80.515.08Not reportedNot reportedNot reported
SWT, Week 22 (n=241,240)

Analysis denominator · Participants

GroupSource count
Pazopanib 800 mg241
Sunitinib 50 mg240
Values in Scores on a scale · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Pazopanib 800 mg85.413.48Not reportedNot reportedNot reported
Sunitinib 50 mg81.415.04Not reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        spread
        22.13
        value
        71.7
      2. group Id
        OG001
        spread
        22.38
        value
        71.3
    denoms
    1. counts
      1. group Id
        OG000
        value
        383
      2. group Id
        OG001
        value
        386
      units
      Participants
    title
    ET, Week 4 (n=383,386)
  2. categories
    1. measurements
      1. group Id
        OG000
        spread
        21.62
        value
        73.4
      2. group Id
        OG001
        spread
        19.37
        value
        73.4
    denoms
    1. counts
      1. group Id
        OG000
        value
        321
      2. group Id
        OG001
        value
        346
      units
      Participants
    title
    ET, Week 10 (n=321,346)
  3. categories
    1. measurements
      1. group Id
        OG000
        spread
        21.56
        value
        73.9
      2. group Id
        OG001
        spread
        21.43
        value
        72.9
    denoms
    1. counts
      1. group Id
        OG000
        value
        296
      2. group Id
        OG001
        value
        293
      units
      Participants
    title
    ET, Week 16 (n=296,293)
  4. categories
    1. measurements
      1. group Id
        OG000
        spread
        21.40
        value
        73.0
      2. group Id
        OG001
        spread
        20.43
        value
        73.4
    denoms
    1. counts
      1. group Id
        OG000
        value
        250
      2. group Id
        OG001
        value
        250
      units
      Participants
    title
    ET, Week 22 (n=250,250)
  5. categories
    1. measurements
      1. group Id
        OG000
        spread
        24.00
        value
        66.3
      2. group Id
        OG001
        spread
        23.59
        value
        58.5
    denoms
    1. counts
      1. group Id
        OG000
        value
        340
      2. group Id
        OG001
        value
        360
      units
      Participants
    title
    FSE, Week 4 (n=340,360)
  6. categories
    1. measurements
      1. group Id
        OG000
        spread
        23.09
        value
        66.0
      2. group Id
        OG001
        spread
        22.23
        value
        56.0
    denoms
    1. counts
      1. group Id
        OG000
        value
        298
      2. group Id
        OG001
        value
        323
      units
      Participants
    title
    FSE, Week 10 (n=298,323)
  7. categories
    1. measurements
      1. group Id
        OG000
        spread
        23.01
        value
        65.0
      2. group Id
        OG001
        spread
        22.02
        value
        56.6
    denoms
    1. counts
      1. group Id
        OG000
        value
        274
      2. group Id
        OG001
        value
        277
      units
      Participants
    title
    FSE, Week 16 (n=274,277)
  8. categories
    1. measurements
      1. group Id
        OG000
        spread
        22.62
        value
        67.1
      2. group Id
        OG001
        spread
        21.28
        value
        57.8
    denoms
    1. counts
      1. group Id
        OG000
        value
        235
      2. group Id
        OG001
        value
        232
      units
      Participants
    title
    FSE, Week 22 (n=235, 232)
  9. categories
    1. measurements
      1. group Id
        OG000
        spread
        15.49
        value
        80.9
      2. group Id
        OG001
        spread
        15.23
        value
        79.0
    denoms
    1. counts
      1. group Id
        OG000
        value
        355
      2. group Id
        OG001
        value
        374
      units
      Participants
    title
    SWT, Week 4 (n=355,374)
  10. categories
    1. measurements
      1. group Id
        OG000
        spread
        13.74
        value
        84.5
      2. group Id
        OG001
        spread
        15.15
        value
        80.4
    denoms
    1. counts
      1. group Id
        OG000
        value
        309
      2. group Id
        OG001
        value
        336
      units
      Participants
    title
    SWT, Week 10 (n=309,336)
  11. categories
    1. measurements
      1. group Id
        OG000
        spread
        14.77
        value
        85.3
      2. group Id
        OG001
        spread
        15.08
        value
        80.5
    denoms
    1. counts
      1. group Id
        OG000
        value
        287
      2. group Id
        OG001
        value
        284
      units
      Participants
    title
    SWT, Week 16 (n=287,284)
  12. categories
    1. measurements
      1. group Id
        OG000
        spread
        13.48
        value
        85.4
      2. group Id
        OG001
        spread
        15.04
        value
        81.4
    denoms
    1. counts
      1. group Id
        OG000
        value
        241
      2. group Id
        OG001
        value
        240
      units
      Participants
    title
    SWT, Week 22 (n=241,240)
denoms
  1. counts
    1. group Id
      OG000
      value
      383
    2. group Id
      OG001
      value
      386
    units
    Participants
description
The CTSQ assesses 3 domains related to the participant's satisfaction with cancer therapy: Expectations of Therapy (ET), Feelings about Side Effects (FSE), and Satisfaction with Therapy (SWT). Participants shared their thoughts on their cancer therapy (9 questions), their satisfaction with their most recently administered cancer therapy (6 questions), and if they would take the same cancer therapy if given the choice to do so again. All questions were assessed on a 5-point scale; 1, never; 5, always. Scores were averaged and transformed to a 0-100 scale; higher scores represent better treatment satisfaction.
dispersion Type
Standard Deviation
groups
  1. description
    Participants were administered pazopanib 800 mg (2 x 400 mg tablets) orally OD continuously. Pazopanib was to be taken at least one hour before or at least two hours after a meal. Participants received study treatment until disease progression, death, unacceptable toxicity, or withdrawal of consent for any other reasons.
    id
    OG000
    title
    Pazopanib 800 mg
  2. description
    Participants were administered sunitinib 50 mg orally once daily in 6-week cycles (4 weeks of treatment, followed by 2 weeks without treatment). Participants received study treatment until disease progression, death, unacceptable toxicity, or withdrawal of consent for any other reasons.
    id
    OG001
    title
    Sunitinib 50 mg
param Type
MEAN
population Description
Intent-to-Treat (ITT) Population. Analysis was based on the assigned randomized treatment, not on the actual treatment received/not received. Participants missing scores at early time points were excluded from the analysis at those time points. Mean total score was calculated at each assessment week.
reporting Status
POSTED
time Frame
Day 28 of Cycles 1-4 (average of Weeks 4, 10, 16, and 22, respectively)
title
Summary of Analysis for the Cancer Treatment Satisfaction Questionnaire (CTSQ) Score at Day 28 of Cycles 1-4
type
SECONDARY
unit Of Measure
Scores on a scale

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice